Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant icotinib plus bevacizumab in resectable EGFR-mutant NSCLC (phase II, single-arm)
ChiCTR2400089589Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of icotinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Major pathologic response rate (MPR) and Event-free survival (EFS). Planned start Sep 2024; status: not yet recruiting.
02
Drugs
icotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400089589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089589.